Ad-hoc | 8 September 2003 20:59

Rhein Biotech N.V. english

Rhein Biotech: Registration of the hepatitis B vaccine SUPERVAX in Argentina Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Rhein Biotech N.V. announces the registration of the vaccine SUPERVAX for effective prophylaxis of hepatitis B infections in Argentina. The vaccine has been developed by Rhein based on a hepatitis B antigen produced through the hansenula polymorpha expression system. It is combined with the fully synthetic adjuvant RC-529 developed by Corixa Corporation (USA). SUPERVAX will be the first licensed vaccine in the world containing RC-529 from Corixa. Clinical trials have demonstrated a solid protection against hepatitis B in more than 95 % of vaccinees after two vaccinations given one month apart. This is an important step in the development of novel vaccines. The vaccine will be launched next year in Argentina. The expansion to the rest of Latin America and to other international markets is planned in the following years. end of ad-hoc-announcement (c)DGAP 08.09.2003 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: Rhein Biotech is a member of the Berna Biotech Group, a leading player for innovation in vaccines. For further information: Rhein Biotech N.V. Company Contact: Béatrice Keller Communications Manager investor.relations@bernabiotech.com ——————————————————————————– WKN: 919544; ISIN: NL0000230324; Index: Listed: Geregelter Markt in Frankfurt (General Standard); Freiverkehr in Düsseldorf, Hamburg, Hannover, München und Stuttgart 082059 Sep 03